Peter Attia

Peter Attia is the skeptic in the room. Trained at Johns Hopkins and the NIH, he wrote "Outlive" and hosts "The Drive" (300M+ downloads). He calls BPC-157 "still the Wild West" because it lacks completed human randomized controlled trials. That caution is the point.

Where Attia does engage with peptides is GLP-1 receptor agonists. He prescribes semaglutide and tirzepatide clinically and was one of the first physicians to publicly flag that 39% of weight loss from the STEP 1 trial was lean tissue. His protocol pairs standard FDA titration with resistance training and high-protein intake (1g per pound of bodyweight) to counteract that muscle loss.

One protocol is tracked on this page. It reflects a prescriber's clinical perspective rather than personal biohacking. When Attia appeared on The Drive with Derek (MPMD) in Episode 274, his stance was clear: promising for healing and recovery, but don't pretend the evidence is there yet.

Protocols by Peter

1 disclosed protocol with verified dosing details.

Peter Attia's GLP-1 Clinical Perspective

FDA Label

Peter Attia prescribes GLP-1 agonists clinically and flagged the lean mass loss problem early: 39% of weight lost in the STEP 1 trial was lean tissue. His protocol follows standard FDA titration (0.25mg to 1mg+ weekly) but pairs it with resistance training and 1g protein per pound of bodyweight. This is a prescriber's perspective, not personal biohacking. DEXA scans and metabolic panels required.

Weight LossBeginnerPartial Dosing·3 phases·12 weeks·$200-1000/mo

SemaglutideTirzepatide

via Peter Attia

All verified sources where Peter discussed peptide protocols.